These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 26164790

  • 1. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
    Fukuyama T, Tschernig T, Qi Y, Volmer DA, Bäumer W.
    Eur J Pharmacol; 2015 Oct 05; 764():278-282. PubMed ID: 26164790
    [Abstract] [Full Text] [Related]

  • 2. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
    Fukuyama T, Ehling S, Cook E, Bäumer W.
    J Pharmacol Exp Ther; 2015 Sep 05; 354(3):394-405. PubMed ID: 26159873
    [Abstract] [Full Text] [Related]

  • 3. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.
    Fukuyama T, Ganchingco JR, Bäumer W.
    Eur J Pharmacol; 2017 Jan 05; 794():20-26. PubMed ID: 27847179
    [Abstract] [Full Text] [Related]

  • 4. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D, O'Dell KM, Bandy JL, Boyce EG.
    Ann Pharmacother; 2013 Nov 05; 47(11):1524-31. PubMed ID: 24285764
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K, Tanaka Y.
    Expert Opin Pharmacother; 2014 Jan 05; 15(1):103-13. PubMed ID: 24188100
    [Abstract] [Full Text] [Related]

  • 13. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M, Mikkelsen C, Eggertsen PP, Stern M, van de Looij A, Deleuran B.
    Ugeskr Laeger; 2017 Oct 30; 179(44):. PubMed ID: 29084618
    [Abstract] [Full Text] [Related]

  • 14. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.
    N Engl J Med; 2017 May 04; 376(18):1723-1736. PubMed ID: 28467869
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
    Bannwarth B, Kostine M, Poursac N.
    Expert Opin Drug Metab Toxicol; 2013 Jun 04; 9(6):753-61. PubMed ID: 23570265
    [Abstract] [Full Text] [Related]

  • 19. Update on Janus kinase antagonists in inflammatory bowel disease.
    Boland BS, Sandborn WJ, Chang JT.
    Gastroenterol Clin North Am; 2014 Sep 04; 43(3):603-17. PubMed ID: 25110261
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.